Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

Fiat Chrysler intends to invest a total of EUR 700 million in the establishment of a production line for a new electric version of its 500 model (BEV), according to a top executive from the company.

The investment represents part of a EUR 5 billion investment plan, which is to be carried out in Italy up to 2021.

As of 7:02 GMT on Friday the shares of Fiat Chrysler were losing 0.54% (EUR 0.066) on the day to trade at EUR 12.270 on the Milan stock exchange.

In New York, Fiat Chrysler shares closed lower for the fifth time in the past eleven trading sessions on Thursday. The stock went down 0.43% ($0.06) to $13.95, after touching an intraday low at $13.87, or a price level not seen since July 2nd ($13.85).

Shares of Fiat Chrysler Automobiles NV have retreated 3.53% so far this year, following an 18.95% drop in 2018.

According to Pietro Gorlier, Fiat Chryslers Chief Operating Officer for Europe, Middle East and Africa, the first robot of the future electric 500 assembly line was installed on July 11th at its Mirafiori plant in Turin. It is expected to manufacture 80 000 vehicles per year, beginning from the second quarter of 2020.

Analyst stock price forecast and recommendation

According to CNN Money, the 22 analysts, offering 12-month forecasts regarding Fiat Chrysler’s stock price, have a median target of $15.81, with a high estimate of $21.46 and a low estimate of $11.28. The median estimate represents a 13.34% upside compared to the closing price of $13.95 on July 11th.

The same media also reported that at least 13 out of 24 surveyed investment analysts had rated Fiat Chrysler’s stock as “Hold”, while 8 – as “Buy”. On the other hand, 1 analyst had recommended selling the stock.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • China’s 10-Year Bond Yield Surges to 1.865%, Its Highest Level in 2025China’s 10-Year Bond Yield Surges to 1.865%, Its Highest Level in 2025 Key momentsChina's 10-year bond yield hit 1.865% on Monday, a 25 basis-point rise from January lows. The country’s fiscal deficit amounts to 4% of GDP, with CN¥1.3 trillion in bonds planned for 2025. MSCI China rose nearly 20%, while […]
  • Gold gains on Fed commentsGold gains on Fed comments Gold marked daily gains on Tuesday as comments by Dallas and Minneapolis Fed presidents curbed speculations of an earlier-than-expected deceleration of the central banks monetary easing program.On the Comex division of the New York […]
  • EUR/USD lower on downbeat French manufacturing production data, while Syria concerns subsidedEUR/USD lower on downbeat French manufacturing production data, while Syria concerns subsided The euro was trading on lower levels against the US dollar on Tuesday, after a report showed that French manufacturing production unexpectedly contracted and as concerns over a possible military strike against Syria subsided.EUR/USD hit a […]
  • WTI futures hold near 1-month high on US fuel demand, Fed minutesWTI futures hold near 1-month high on US fuel demand, Fed minutes West Texas Intermediate crude fell in early European trading on Thursday but held near the highest level in a month after a spike in US gasoline demand, coupled with persisting tension in eastern Ukraine. Wednesdays Fed minutes, which […]
  • Soft futures mixed, Brazil avoids frostSoft futures mixed, Brazil avoids frost Soft futures were mixed on Thursday with sugar and cocoa advancing, while robusta fell and arabica extended its biggest tumble in five weeks as Brazil avoided frost damage.On the ICE Futures U.S., arabica coffee for September delivery […]
  • Treace Medical stock downgraded to “Neutral” at UBSTreace Medical stock downgraded to “Neutral” at UBS Treace Medical Concepts Inc's (NASDAQ: TMCI) shares retreated more than 5% on Thursday, after UBS cut its investment rating on the stock to "Neutral".UBS cited limited visibility into Treace Medical's ability to preserve a market share […]